Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI4RUI)

Drug Name

PF-07038124 Drug Info

Synonyms

PF-07038124; M6ZU548FWD; PF07038124; UNII-M6ZU548FWD; 2415085-44-6; Pyridine, 3-((4R)-2-hydroxy-1,2-oxaborolan-4-yl)-5-(4-methoxy-3-propoxyphenyl)-; GTPL11950; US11559538, Example 4; BDBM589740; GLXC-25702; Example 4 [US2020108083A1]; PF 07038124 [WHO-DD]; HY-144683; CS-0433935; (R)-4-(5-(4-Methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; 3-[(4R)-2-hydroxyoxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)pyridine

Indication

Disease Entry	ICD 11	Status	REF
Atopic dermatitis	EA80	Phase 2	[1]
Psoriasis	EA90	Phase 2	[1]

Cross-matching ID

PubChem CID: 148293990
TTD Drug ID: DMI4RUI

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Phosphodiesterase 4 (PDE4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[3]
Oxtriphylline	DMLHSE3	Cough	MD12	Approved	[4]
Roflumilast	DMPGHY8	Asthma	CA23	Approved	[5]
Ibudilast	DM4LSPN	Castleman's disease	4B2Y	Approved	[6]
crisaborole	DMNVKU6	Atopic dermatitis	EA80	Approved	[7]
Arofylline	DM84AD1	Chronic obstructive pulmonary disease	CA22	Phase 3	[8]
ARQ-151	DML61S4	Atopic dermatitis	EA80	Phase 3	[9]
SUN13834	DMPK34E	Gram-positive bacterial infection	1B74-1G40	Phase 2	[10]
ONO-6126	DMRT28X	Chronic obstructive pulmonary disease	CA22	Phase 2	[8]
E6005	DM1S489	Atopic dermatitis	EA80	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 4 (PDE4)	TTV5CGO	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05375955) A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSE LEVELS OF PF-07038124 OINTMENT FOR 12 WEEKS IN PARTICIPANTS 12 YEARS AND OLDER AND WITH MILD-TO-MODERATE ATOPIC DERMATITIS OR MILD-TO-SEVERE PLAQUE PSORIASIS. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Pfzer
3	Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
6	Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
7	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
8	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
9	Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.
10	Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
11	Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.